Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $94 | $88 | $97 | $100 |
| - Cash | $16 | $75 | $54 | $42 |
| + Debt | $1 | $0 | $0 | $0 |
| Enterprise Value | $79 | $14 | $43 | $58 |
| Revenue | $0 | $2 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | – | 0.7% | – | – |
| EBITDA | $13 | -$4 | -$10 | -$3 |
| % Margin | – | -223.5% | – | – |
| Net Income | $13 | -$8 | -$10 | -$20 |
| % Margin | – | -382.1% | – | – |
| EPS Diluted | 0.31 | -0.19 | -0.26 | -0.48 |
| % Growth | 263.2% | 26.9% | 45.8% | – |
| Operating Cash Flow | -$4 | -$4 | -$2 | -$7 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$4 | -$4 | -$2 | -$7 |